Table 2.
Disease markers and outcomes in control versus rituximab treatment groups
| Markers and Outcomes | Baseline | End of Study | ||||
|---|---|---|---|---|---|---|
| Control, n=11 | Rituximab, n=11 | P Value | Control, n=10 | Rituximab, n=10 | P Value | |
| Biochemical markersa | ||||||
| IgA, mg/ml | 4.7±2.0 | 5.0±1.8 | 0.68 | 4.6±1.9 | 4.4±1.4 | 0.77 |
| Gd-IgA1, per 100 ng IgA, U | 56.8±6.9 | 54.8±10.0 | 0.58 | 58.9±5.6 | 60.5±13.0 | 0.73 |
| IgG autoantibodies, U/ml | 858.4±647.3 | 1492.5±1672.9 | 0.25 | 1075±908.7 | 1751.3±2469.4 | 0.42 |
| Outcomes, n | ||||||
| Patients with >50% reduction in proteinuria | — | — | — | 3 | 3 | >0.99 |
| Patients with >50% increase in proteinuria | — | — | — | 2 | 1 | 0.54 |
| Patients with <500 mg/d protein | — | — | — | 2 | 2 | >0.99 |
—, not applicable.
a
Data presented as mean ±SD.